Peptides by condition · Weight, blood sugar, liver and gut
Peptides studied for type 2 diabetes
Checked against our study pages and the FDA labelsPublished by PepVault
Our library holds 44 study pages on type 2 diabetes: 41 in people (39 of them meta-analyses or randomized trials), and 3 in animals. They studied 19 compounds, with this many study pages each: Retatrutide 5, Dulaglutide 4, Semaglutide 4, Tirzepatide 4, Ecnoglutide 4, Exenatide 3, Semaglutide (oral) 2, Orforglipron 2, CagriSema 2, Mazdutide 2, Amycretin 2, Pramlintide 2, Liraglutide 1, Efinopegdutide 1, Cagrilintide 1, Tesamorelin 1, GHRP-6 1, MOTS-c 2 and NSI-189 1.
What the research on type 2 diabetes looks like
Type 2 diabetes is a long-term condition in which the body stops responding well to insulin and blood sugar runs high. Peptide research on it is led by the GLP-1 drugs and their newer two- and three-hormone relatives, tested against placebo, insulin and each other; several of these drugs began as diabetes medicines.
The main number in a diabetes trial is HbA1c, a blood test that reflects average blood sugar over the past few months. Larger trials also count heart attacks, strokes and kidney decline, because those are what diabetes does over the years.
Check what a drug was compared with: a placebo, a lower dose or another diabetes drug. A study in diabetic rats or mice shows a mechanism, not what a person’s blood sugar will do.

Model. Individual results vary.
The 44 studies, by compound
Grouped by the compound each study is filed under, and within each, strongest design first. Each line gives the design, who was studied, how many and the year, before the finding.
Retatrutide
5 in peopleFor type 2 diabetes, 5 of our study pages are filed under Retatrutide: 4 randomized trials and 1 clinical trial in people. The largest in people enrolled 537 people and was published in 2026. They were published from 2022 to 2026, in Lancet, Diabetes Obes Metab, Lancet Diabetes Endocrinol and Kidney Int Rep.
Retatrutide has no FDA-approved product: Drugs@FDA lists no application for it, and FDA writes that it is not a component of any FDA-approved drug.
- Randomized trial in people · 537 people · 2026Retatrutide: HbA1c down up to 1.94% in TRANSCEND-T2D-1
- Randomized trial in people · 275 people · 2025Retatrutide: less hunger and overeating vs placebo at higher doses
- Randomized trial in people · 189 people · 2025Retatrutide: 26.1% fat mass loss at 36 weeks in type 2 diabetes
- Randomized trial in people · 72 people · 2022Retatrutide: up to 8.96 kg placebo-adjusted weight loss in 12 weeks
- Clinical trial in people · 2025Retatrutide 12 mg: UACR 37.0% lower vs placebo in type 2 diabetes
Dulaglutide
4 in peopleFor type 2 diabetes, 4 of our study pages are filed under Dulaglutide: 4 randomized trials in people. The largest in people enrolled 9,901 people and was published in 2019. They were published from 2018 to 2025, in Lancet, Lancet Diabetes Endocrinol and Ann Intern Med.
FDA-approved, with a use tied to type 2 diabetes on its label: Trulicity (injection) for blood sugar control in type 2 diabetes (adults and children 10 and older), and lowering heart risk in adults with type 2 diabetes and heart disease or several heart risk factors.
- Randomized trial in people · 9,901 people · 2019Dulaglutide lowered major cardiovascular events (HR 0.88) in REWIND
- Randomized trial in people · 1,201 people · 2018Dulaglutide cut HbA1c and weight less than semaglutide in SUSTAIN 7
- Randomized trial in people · 636 people · 2022Dulaglutide cut HbA1c 1.3 vs 2.4 to 2.8 with tirzepatide at 52 weeks
- Randomized trial in people · 282 people · 2025Dulaglutide: switching to tirzepatide beat dose escalation on HbA1c
Semaglutide
4 in peopleFor type 2 diabetes, 4 of our study pages are filed under Semaglutide: 4 randomized trials in people. The largest in people enrolled 3,533 people and was published in 2024. They were published from 2016 to 2026, in N Engl J Med and Lancet.
FDA-approved, with a use tied to type 2 diabetes on its label: Ozempic (injection) for blood sugar control in adults with type 2 diabetes, and lowering the risk of heart attack, stroke and kidney decline in those with heart or kidney disease; Rybelsus (tablet) for blood sugar control in adults with type 2 diabetes, and lowering the risk of heart attack and stroke in those at high risk; Ozempic (tablet) for blood sugar control in adults with type 2 diabetes, and lowering the risk of heart attack and stroke in those at high risk (the same label as Rybelsus). Under Wegovy it is approved for other uses.
- Randomized trial in people · 3,533 people · 2024Semaglutide: 24% lower risk of major kidney events in FLOW
- Randomized trial in people · 3,297 people · 2016Semaglutide: 6.6% vs 8.9% heart or stroke events in SUSTAIN-6
- Randomized trial in people · 1,698 people · 2026Semaglutide (oral): smaller HbA1c drop than orforglipron in ACHIEVE-3
- Randomized trial in people · 1,210 people · 2021Semaglutide 2.4 mg: 9.6% weight loss at 68 weeks in STEP 2
Tirzepatide
4 in peopleFor type 2 diabetes, 4 of our study pages are filed under Tirzepatide: 4 randomized trials in people. The largest in people enrolled 1,879 people and was published in 2021. They were published from 2021 to 2023, in N Engl J Med, JAMA and Lancet.
FDA-approved, with a use tied to type 2 diabetes on its label: Mounjaro (injection) for blood sugar control in type 2 diabetes (adults and children 10 and older), and lowering heart risk in adults with type 2 diabetes. Under Zepbound it is approved for other uses.
- Randomized trial in people · 1,879 people · 2021Tirzepatide beat semaglutide 1 mg on HbA1c at 40 weeks in SURPASS-2
- Randomized trial in people · 1,428 people · 2023Tirzepatide: HbA1c fell 2.1% vs 1.1% with insulin lispro in SURPASS-6
- Randomized trial in people · 938 people · 2023Tirzepatide 15 mg: 14.7% weight loss at 72 weeks in SURMOUNT-2
- Randomized trial in people · 478 people · 2021Tirzepatide: HbA1c fell up to 2.07% at 40 weeks in SURPASS-1
Ecnoglutide
4 in peopleFor type 2 diabetes, 4 of our study pages are filed under Ecnoglutide: 1 meta-analysis and 3 randomized trials in people. The largest in people pooled 1,643 people and was published in 2026. They were published from 2024 to 2026, in Endocrinol Diabetes Metab, Lancet Diabetes Endocrinol and Nat Commun.
Ecnoglutide has no FDA-approved product: Drugs@FDA lists no application for it.
- Meta-analysis in people · 1,643 people · 2026Ecnoglutide lowered HbA1c and weight in type 2 diabetes: meta-analysis
- Randomized trial in people · 623 people · 2025Ecnoglutide: HbA1c fell up to 1.91% vs 1.65% with dulaglutide
- Randomized trial in people · 211 people · 2026Ecnoglutide: HbA1c fell up to 2.43% at 24 weeks in EECOH-1
- Randomized trial in people · 145 people · 2024Ecnoglutide: HbA1c fell up to 2.39% at 20 weeks in type 2 diabetes
Exenatide
3 in peopleFor type 2 diabetes, 3 of our study pages are filed under Exenatide: 3 randomized trials in people. The largest in people enrolled 14,752 people and was published in 2017. They were published from 2017 to 2021, in N Engl J Med, Diabetes Care and Diabetes Obes Metab.
FDA-approved, with a use tied to type 2 diabetes on its label: Byetta (injection) for blood sugar control, with diet and exercise, in adults with type 2 diabetes.
- Randomized trial in people · 14,752 people · 2017Exenatide: no significant drop in heart events vs placebo in EXSCEL
- Randomized trial in people · 813 people · 2018Exenatide ER: 0.9% HbA1c drop vs 1.5% with semaglutide in SUSTAIN 3
- Randomized trial in people · 66 people · 2021Exenatide plus dapagliflozin: UACR fell 39.6% vs 11.0% on placebo
Semaglutide (oral)
2 in peopleFor type 2 diabetes, 2 of our study pages are filed under Semaglutide (oral): 2 randomized trials in people. The largest in people enrolled 9,650 people and was published in 2025. They were published from 2019 to 2025, in N Engl J Med.
FDA-approved, with a use tied to type 2 diabetes on its label: Rybelsus (tablet) for blood sugar control in adults with type 2 diabetes, and lowering the risk of heart attack and stroke in those at high risk; Ozempic (tablet) for blood sugar control in adults with type 2 diabetes, and lowering the risk of heart attack and stroke in those at high risk (the same label as Rybelsus). Under Wegovy it is approved for other uses.
- Randomized trial in people · 9,650 people · 2025Semaglutide (oral): fewer major heart events than placebo in SOUL
- Randomized trial in people · 3,183 people · 2019Semaglutide (oral): heart risk not higher than placebo in PIONEER 6
Orforglipron
2 in peopleFor type 2 diabetes, 2 of our study pages are filed under Orforglipron: 2 randomized trials in people. The largest in people enrolled 2,749 people and was published in 2026. All were published in 2026, in Lancet.
FDA-approved for other uses, not for type 2 diabetes: Foundayo (tablet) for weight loss and keeping it off, in adults with obesity or with excess weight and a weight-related condition.
- Randomized trial in people · 2,749 people · 2026Orforglipron: heart events no worse than insulin in ACHIEVE-4
- Randomized trial in people · 1,613 people · 2026Orforglipron: 9.6% weight loss at 72 weeks in ATTAIN-2
CagriSema
2 in peopleFor type 2 diabetes, 2 of our study pages are filed under CagriSema: 2 randomized trials in people. The largest in people enrolled 1,206 people and was published in 2025. They were published from 2025 to 2026, in N Engl J Med and Lancet.
CagriSema, cagrilintide combined with semaglutide, has no FDA-approved product: Drugs@FDA lists no application with cagrilintide in it. Semaglutide on its own is approved (Ozempic, Wegovy).
- Randomized trial in people · 1,206 people · 2025CagriSema: 13.7% weight loss at 68 weeks in REDEFINE 2
- Randomized trial in people · 274 people · 2026CagriSema: HbA1c down 2.33% at 40 weeks in REIMAGINE 3
Mazdutide
2 in peopleFor type 2 diabetes, 2 of our study pages are filed under Mazdutide: 2 randomized trials in people. The largest in people enrolled 731 people and was published in 2026. All were published in 2026, in Nature.
Mazdutide has no FDA-approved product: Drugs@FDA lists no application for it. FDA writes that it has warned companies that illegally sold unapproved drugs containing mazdutide, among others, labeled “for research purposes”.
- Randomized trial in people · 731 people · 2026Mazdutide beat dulaglutide on HbA1c and weight at 28 weeks
- Randomized trial in people · 320 people · 2026Mazdutide: HbA1c fell 2.15% at 24 weeks in type 2 diabetes
Amycretin
2 in peopleFor type 2 diabetes, 2 of our study pages are filed under Amycretin: 2 randomized trials in people. The largest in people enrolled 262 people and was published in 2026. All were published in 2026, in Lancet.
Amycretin has no FDA-approved product: Drugs@FDA lists no application for it.
- Randomized trial in people · 262 people · 2026Amycretin: HbA1c fell up to 1.7% at 36 weeks in type 2 diabetes
- Randomized trial in people · 186 people · 2026Amycretin: oral 50 mg arm cut HbA1c by 1.4% at 36 weeks
Pramlintide
2 in peopleFor type 2 diabetes, 2 of our study pages are filed under Pramlintide: 1 meta-analysis and 1 randomized trial in people. The largest in people enrolled 24 people and was published in 2002. They were published from 2002 to 2003, in Diabetes Obes Metab and Horm Metab Res.
FDA-approved, with a use tied to type 2 diabetes on its label: Symlin for adding to mealtime insulin in type 1 or type 2 diabetes when insulin alone has not reached the blood sugar goal.
- Meta-analysis in people · 2003Pramlintide: HbA1c down 0.43% vs placebo at 26 weeks with insulin
- Randomized trial in people · 24 people · 2002Pramlintide lowered post-meal glucagon and glucose in type 2 diabetes
Liraglutide
1 in peopleFor type 2 diabetes, 1 of our study pages is filed under Liraglutide: 1 randomized trial in people. It enrolled 9,340 people and was published in 2016, in N Engl J Med.
FDA-approved, with a use tied to type 2 diabetes on its label: Victoza (injection) for blood sugar control in type 2 diabetes (adults and children 10 and older), and lowering heart risk in adults with type 2 diabetes and heart disease. Under Saxenda it is approved for other uses.
- Randomized trial in people · 9,340 people · 2016Liraglutide: 13.0% vs 14.9% major cardiovascular events in LEADER
Efinopegdutide
1 in peopleFor type 2 diabetes, 1 of our study pages is filed under Efinopegdutide: 1 randomized trial in people. It enrolled 195 people and was published in 2021, in Clin Obes.
Efinopegdutide has no FDA-approved product: Drugs@FDA lists no application for it.
- Randomized trial in people · 195 people · 2021Efinopegdutide: up to 7.2% more weight loss than placebo at 12 weeks
Cagrilintide
1 in peopleFor type 2 diabetes, 1 of our study pages is filed under Cagrilintide: 1 randomized trial in people. It enrolled 92 people and was published in 2023, in Lancet.
Cagrilintide has no FDA-approved product: Drugs@FDA lists no application for it, and FDA writes that it is not a component of any FDA-approved drug.
- Randomized trial in people · 92 people · 2023Cagrilintide with semaglutide: 15.6% weight loss in type 2 diabetes
Tesamorelin
1 in peopleFor type 2 diabetes, 1 of our study pages is filed under Tesamorelin: 1 randomized trial in people. It enrolled 53 people and was published in 2017, in PLoS One.
FDA-approved for other uses, not for type 2 diabetes: Egrifta (injection) for reducing excess belly fat in adults with HIV and lipodystrophy (its label says it is not for weight loss).
- Randomized trial in people · 53 people · 2017Tesamorelin: no change in glucose control in type 2 diabetes
GHRP-6
1 in peopleFor type 2 diabetes, 1 of our study pages is filed under GHRP-6: 1 clinical trial in people. It enrolled 12 people and was published in 2004, in Diabetes Res Clin Pract.
GHRP-6 has no FDA-approved product: Drugs@FDA lists no application for it.
- Clinical trial in people · 12 people · 2004GHRP-6 + GHRH: high blood sugar cut GH response in type 2 diabetes
MOTS-c
2 in animalsFor type 2 diabetes, 2 of our study pages are filed under MOTS-c: 2 animal studies (mice and rats). None of them is in people. All were published in 2025, in Exp Mol Med and Front Physiol.
MOTS-c has no FDA-approved product: Drugs@FDA lists no application for it.
- Animal study in mice · 2025MOTS-c reduced islet cell senescence and glucose intolerance in mice
- Animal study in rats · 2025MOTS-c improved heart mitochondrial respiration in diabetic rats
NSI-189
1 in animalsFor type 2 diabetes, 1 of our study pages is filed under NSI-189: 1 animal study (rats). It was published in 2022, in J Diabetes Res.
NSI-189 has no FDA-approved product: Drugs@FDA lists no application for it.
- Animal study in rats · 2022NSI-189 eased nerve damage and memory problems in diabetic rats
Side by side
For the 19 compounds on this page: studies in people, studies in animals or cells, the size of the largest study in people, and the FDA status from the labels our status pages read (a dash where they hold no record).
| Compound | In people | Animals or cells | Largest in people | FDA |
|---|---|---|---|---|
| Retatrutide | 5 | 0 | 537 | Not approved |
| Dulaglutide | 4 | 0 | 9,901 | Approved, a use tied to it |
| Semaglutide | 4 | 0 | 3,533 | Approved, a use tied to it |
| Tirzepatide | 4 | 0 | 1,879 | Approved, a use tied to it |
| Ecnoglutide | 4 | 0 | 1,643 | Not approved |
| Exenatide | 3 | 0 | 14,752 | Approved, a use tied to it |
| Semaglutide (oral) | 2 | 0 | 9,650 | Approved, a use tied to it |
| Orforglipron | 2 | 0 | 2,749 | Approved for other uses |
| CagriSema | 2 | 0 | 1,206 | Not approved |
| Mazdutide | 2 | 0 | 731 | Not approved |
| Amycretin | 2 | 0 | 262 | Not approved |
| Pramlintide | 2 | 0 | 24 | Approved, a use tied to it |
| Liraglutide | 1 | 0 | 9,340 | Approved, a use tied to it |
| Efinopegdutide | 1 | 0 | 195 | Not approved |
| Cagrilintide | 1 | 0 | 92 | Not approved |
| Tesamorelin | 1 | 0 | 53 | Approved for other uses |
| GHRP-6 | 1 | 0 | 12 | Not approved |
| MOTS-c | 0 | 2 | — | Not approved |
| NSI-189 | 0 | 1 | — | Not approved |
- In people
- 5
- Animals or cells
- 0
- Largest in people
- 537
- FDA
- Not approved
- In people
- 4
- Animals or cells
- 0
- Largest in people
- 9,901
- FDA
- Approved, a use tied to it
- In people
- 4
- Animals or cells
- 0
- Largest in people
- 3,533
- FDA
- Approved, a use tied to it
- In people
- 4
- Animals or cells
- 0
- Largest in people
- 1,879
- FDA
- Approved, a use tied to it
- In people
- 4
- Animals or cells
- 0
- Largest in people
- 1,643
- FDA
- Not approved
- In people
- 3
- Animals or cells
- 0
- Largest in people
- 14,752
- FDA
- Approved, a use tied to it
- In people
- 2
- Animals or cells
- 0
- Largest in people
- 9,650
- FDA
- Approved, a use tied to it
- In people
- 2
- Animals or cells
- 0
- Largest in people
- 2,749
- FDA
- Approved for other uses
- In people
- 2
- Animals or cells
- 0
- Largest in people
- 1,206
- FDA
- Not approved
- In people
- 2
- Animals or cells
- 0
- Largest in people
- 731
- FDA
- Not approved
- In people
- 2
- Animals or cells
- 0
- Largest in people
- 262
- FDA
- Not approved
- In people
- 2
- Animals or cells
- 0
- Largest in people
- 24
- FDA
- Approved, a use tied to it
- In people
- 1
- Animals or cells
- 0
- Largest in people
- 9,340
- FDA
- Approved, a use tied to it
- In people
- 1
- Animals or cells
- 0
- Largest in people
- 195
- FDA
- Not approved
- In people
- 1
- Animals or cells
- 0
- Largest in people
- 92
- FDA
- Not approved
- In people
- 1
- Animals or cells
- 0
- Largest in people
- 53
- FDA
- Approved for other uses
- In people
- 1
- Animals or cells
- 0
- Largest in people
- 12
- FDA
- Not approved
- In people
- 0
- Animals or cells
- 2
- Largest in people
- —
- FDA
- Not approved
- In people
- 0
- Animals or cells
- 1
- Largest in people
- —
- FDA
- Not approved
What the studies did not show
Each study page names its own limits. These are the questions still open, in the study pages’ words.
- Retatrutide: HbA1c down up to 1.94% in TRANSCEND-T2D-1The trial lasted 40 weeks, compared retatrutide only with placebo rather than other diabetes drugs, and included people with fairly recent diabetes (mean 2.5 years) using no other diabetes medicine. It was funded by Eli Lilly and Company.
- Dulaglutide lowered major cardiovascular events (HR 0.88) in REWINDOnly one dose, 1.5 mg weekly, was tested, and only in people aged 50 or older with type 2 diabetes and cardiovascular disease or risk factors. The trial was funded by Eli Lilly and Company.
- Semaglutide: 24% lower risk of major kidney events in FLOWThe trial included only people with type 2 diabetes and chronic kidney disease within set eGFR and urine albumin ranges, tested a single 1.0 mg dose, and was stopped early. It was funded by Novo Nordisk.
- Tirzepatide beat semaglutide 1 mg on HbA1c at 40 weeks in SURPASS-2Patients and doctors knew which drug was given, the trial ran 40 weeks, and tirzepatide was compared only with semaglutide at 1 mg. The trial was funded by Eli Lilly.
- Ecnoglutide lowered HbA1c and weight in type 2 diabetes: meta-analysisThe analysis pools only a handful of trials and mixes placebo and active-drug comparisons, so it can't say how ecnoglutide compares with any single drug. It covers adults with type 2 diabetes only, not people with obesity who don't have diabetes.
- Exenatide: no significant drop in heart events vs placebo in EXSCELThe trial tested only the 2 mg once-weekly form in people with type 2 diabetes, so it does not speak to other doses or to people without diabetes. It was funded by Amylin Pharmaceuticals.
- Semaglutide (oral): fewer major heart events than placebo in SOULThe trial only included people aged 50 or older with type 2 diabetes plus artery or kidney disease, so it does not show the same effect in people without diabetes or at lower risk, and it found no significant kidney benefit. It was funded by Novo Nordisk.
- Orforglipron: 9.6% weight loss at 72 weeks in ATTAIN-2The trial only included adults with type 2 diabetes and an HbA1c of 7-10%, so it does not show results in people without diabetes, and all groups also made lifestyle changes. The study was funded by Eli Lilly and Company.
- CagriSema: 13.7% weight loss at 68 weeks in REDEFINE 2The trial compared CagriSema only with placebo, so it doesn't show how the pair does against either drug alone, and it ran for 68 weeks in people with type 2 diabetes. It was funded by Novo Nordisk.
- Mazdutide beat dulaglutide on HbA1c and weight at 28 weeksThe trial ran for 28 weeks and included only Chinese adults with type 2 diabetes, so it does not show longer-term results or how other groups respond. It compared mazdutide with one dulaglutide dose, not with other diabetes or weight medicines.
- Amycretin: HbA1c fell up to 1.7% at 36 weeks in type 2 diabetesThis was a 36-week dose-finding trial with a small placebo group of 37 people, all of them adults with type 2 diabetes on background metformin. It was funded by Novo Nordisk.
- Pramlintide: HbA1c down 0.43% vs placebo at 26 weeks with insulinThis was a post hoc look at a subset of patients from two earlier trials, chosen after the trials were done rather than planned in advance. It lasted 26 weeks and covered only people with type 2 diabetes already on insulin.
- Liraglutide: 13.0% vs 14.9% major cardiovascular events in LEADERThe trial only enrolled people with type 2 diabetes at high cardiovascular risk, and the prespecified exploratory outcomes were not adjusted for testing many outcomes at once. It was funded by Novo Nordisk and the National Institutes of Health.
- Cagrilintide with semaglutide: 15.6% weight loss in type 2 diabetesThis was a small, 32-week phase 2 trial with no placebo arm, run only in US adults already taking metformin. It was funded by Novo Nordisk.
- Tesamorelin: no change in glucose control in type 2 diabetesThe trial was small and lasted only 12 weeks, so it does not show longer-term effects on blood sugar. It included only people with type 2 diabetes.
- GHRP-6 + GHRH: high blood sugar cut GH response in type 2 diabetesOnly 12 normal-weight men with type 2 diabetes took part, with no women and no group without diabetes. GHRP-6 was always given together with GHRH, so its effect on its own was not tested.
- MOTS-c improved heart mitochondrial respiration in diabetic ratsThis is a short, 3-week study in rats with a diet-and-drug model of diabetes, so it is not a human result. The mitochondrial tests were done on heart tissue samples, so the study does not show effects on heart pumping in living animals or people.
- NSI-189 eased nerve damage and memory problems in diabetic ratsThis was done in rats, so it is not a human result, and it used only one diabetes model. The mitochondrial changes came alongside the nerve and memory gains, which does not show that they caused them.
This page is a reading of published studies, not medical advice. A diagnosis, and what to do about it, is a conversation with a clinician.
Questions
Which peptides have been studied for type 2 diabetes?
Our 44 study pages on type 2 diabetes are filed under 19 compounds, with this many each: Retatrutide 5, Dulaglutide 4, Semaglutide 4, Tirzepatide 4, Ecnoglutide 4, Exenatide 3, Semaglutide (oral) 2, Orforglipron 2, CagriSema 2, Mazdutide 2, Amycretin 2, Pramlintide 2, Liraglutide 1, Efinopegdutide 1, Cagrilintide 1, Tesamorelin 1, GHRP-6 1, MOTS-c 2 and NSI-189 1. Retatrutide has the most.
Have any been tested in people with type 2 diabetes?
Yes: 41 of the 44 were in people, 39 of them meta-analyses or randomized trials (Retatrutide, Dulaglutide, Semaglutide, Tirzepatide, Ecnoglutide, Exenatide, Semaglutide (oral), Orforglipron, CagriSema, Mazdutide, Amycretin, Pramlintide, Liraglutide, Efinopegdutide, Cagrilintide and Tesamorelin). The largest enrolled 14,752 people: “Exenatide: no significant drop in heart events vs placebo in EXSCEL” (2017).
Is any peptide FDA-approved for type 2 diabetes?
Yes, with a use tied to type 2 diabetes on their FDA labels: Dulaglutide as Trulicity; Semaglutide as Ozempic and Rybelsus; Tirzepatide as Mounjaro; Exenatide as Byetta; Semaglutide (oral) as Rybelsus and Ozempic; Pramlintide as Symlin; Liraglutide as Victoza. 12 other compounds here with an FDA record have no use tied to it.
How large were the studies in people on type 2 diabetes?
Of the 41 in people, 39 give their size on our pages: 16 had 1,000 people or more, 17 had 100 to 999 and 6 had fewer than 100. The largest, a randomized trial from 2017, enrolled 14,752.
What did the animal and cell studies on type 2 diabetes use?
3 animal studies (mice and rats), filed under MOTS-c and NSI-189. A result in animals or cells shows what to test next, not what happens in a person.
What is the newest study on type 2 diabetes here?
Of our study pages on type 2 diabetes, the newest is “Ecnoglutide lowered HbA1c and weight in type 2 diabetes: meta-analysis”, a meta-analysis in people published in 2026.
How this page was built
A study page is listed here only where we read its question, design and finding and the study was about this condition: its subjects had the condition, or were an animal or cell model of it, and the study gave them the compound. A study that only mentions the condition is not listed.
Studies are grouped by the compound each is filed under and ordered by design: meta-analyses and randomized trials in people first, then other studies in people, then animals, then cells, and within a group by size and then by year. The FDA status comes from the labels our legal-status and brand pages read.